z-logo
open-access-imgOpen Access
NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer
Author(s) -
Iok In Christine Chio,
Seyed Mehdi Jafarnejad,
Mariano PonzSarvisé,
Youngkyu Park,
Keith Rivera,
Wilhelm Palm,
John P. Wilson,
Vineet Sangar,
Hao Yuan,
Daniel Öhlund,
Kevin Wright,
Dea Filippini,
Eun Jung Lee,
Brandon Da Silva,
Christina Schoepfer,
John E. Wilkinson,
Jonathan M. Buscaglia,
Gina M. DeNicola,
Hervé Tiriac,
Molly Hammell,
Howard C. Crawford,
Edward E. Schmidt,
Craig B. Thompson,
Darryl Pappin,
Nahum Sonenberg,
David A. Tuveson
Publication year - 2016
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2016.06.056
Subject(s) - biology , translation (biology) , pancreatic cancer , messenger rna , cancer research , cancer , microbiology and biotechnology , genetics , gene
Pancreatic cancer is a deadly malignancy that lacks effective therapeutics. We previously reported that oncogenic Kras induced the redox master regulator Nfe2l2/Nrf2 to stimulate pancreatic and lung cancer initiation. Here, we show that NRF2 is necessary to maintain pancreatic cancer proliferation by regulating mRNA translation. Specifically, loss of NRF2 led to defects in autocrine epidermal growth factor receptor (EGFR) signaling and oxidation of specific translational regulatory proteins, resulting in impaired cap-dependent and cap-independent mRNA translation in pancreatic cancer cells. Combined targeting of the EGFR effector AKT and the glutathione antioxidant pathway mimicked Nrf2 ablation to potently inhibit pancreatic cancer ex vivo and in vivo, representing a promising synthetic lethal strategy for treating the disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom